公开(公告)号：US20150291623A1

公开(公告)日：2015-10-15

申请号：US14542367

申请日：2014-11-14

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Mikhail Chafeev ,  Sultan Chowdhury ,  Lauren Fraser ,  Jianmin Fu ,  Jonathan Langille ,  Shifeng Liu ,  Jianyu Sun ,  Shaoyi Sun ,  Serguei Sviridov ,  Mark Wood ,  Alla Yurevna Zenova ,  Qi Jia ,  Jean-Jacques Alexandre Cadieux ,  Simon J. Gauthier ,  Amy Frances Douglas ,  Tom Hsieh ,  Nagasree Chakka ,  Zoran Cikojevic

IPC: C07D513/20 ,  C07D519/00 ,  C07D491/22 ,  C07D491/20 ,  C07D498/20

CPC classification number: C07D513/22 ,  C07D491/10 ,  C07D491/107 ,  C07D491/20 ,  C07D491/22 ,  C07D495/20 ,  C07D498/20 ,  C07D513/20 ,  C07D519/00

Abstract: This invention is directed to spiro-oxindole compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及螺 - 羟吲哚化合物，作为立体异构体，对映体，其互变异构体或其混合物; 或其药学上可接受的盐，溶剂合物或前药用于治疗和/或预防钠通道介导的疾病或病症，例如疼痛。

公开(公告)号：US08933236B2

公开(公告)日：2015-01-13

申请号：US13899469

申请日：2013-05-21

Applicant: Genentech, Inc. ,  Xenon Pharmaceuticals Inc.

Inventor： Sultan Chowdhury ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Qi Jia ,  Daniel Ortwine ,  Brian Safina ,  Shaoyi Sun ,  Daniel P. Sutherlin ,  Alla Yurevna Zenova

IPC: C07C311/51 ,  C07D403/12 ,  C07D213/82 ,  C07D213/64 ,  C07D205/04 ,  C07D311/58 ,  A61K31/445 ,  A61K31/44 ,  A61K31/18 ,  C07D265/30 ,  C07D233/84 ,  C07D257/04 ,  C07C307/06 ,  C07D295/26 ,  C07D207/48 ,  C07D311/70 ,  C07D413/12 ,  C07D451/02 ,  C07D307/12 ,  C07D309/08 ,  C07D311/72 ,  C07D405/12 ,  C07D491/107 ,  C07D211/22 ,  C07D295/192 ,  C07D211/96 ,  C07D307/18

CPC classification number: C07D491/107 ,  A61K31/18 ,  A61K31/397 ,  A61K31/40 ,  A61K31/41 ,  A61K31/4164 ,  A61K31/44 ,  A61K31/5375 ,  C07B2200/05 ,  C07C307/06 ,  C07C311/51 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/10 ,  C07C2602/18 ,  C07C2602/20 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2602/50 ,  C07C2603/66 ,  C07C2603/68 ,  C07C2603/74 ,  C07D205/04 ,  C07D207/46 ,  C07D207/48 ,  C07D209/52 ,  C07D211/22 ,  C07D211/96 ,  C07D213/64 ,  C07D213/82 ,  C07D233/84 ,  C07D257/04 ,  C07D265/30 ,  C07D295/192 ,  C07D295/26 ,  C07D307/12 ,  C07D307/18 ,  C07D309/08 ,  C07D311/58 ,  C07D311/70 ,  C07D311/72 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D451/02 ,  C07D471/08

Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

Abstract translation: 本发明提供具有以下通式的新化合物及其药学上可接受的盐，其中变量RA，下标n，环A，X2，L，下标m，X1，B，R1，R2，R3，R4，R5和RN具有 本文所述的含义，以及含有这些化合物的组合物和使用这些化合物和组合物的方法。

公开(公告)号：US20140336390A1

公开(公告)日：2014-11-13

申请号：US14272297

申请日：2014-05-07

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Jacques Alexandre Cadieux ,  Mikhail Chafeev ,  Sultan Chowdhury ,  Jianmin Fu ,  Qi Ji ,  Stefanie Abel ,  Emad El-Sayed ,  Elke Huthmann ,  Thomas Isarno

IPC: C07D491/20

CPC classification number: C07D491/20 ,  C07D405/04

Abstract: This invention is directed to methods of preparing certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及制备某些螺 - 羟吲哚衍生物的方法，其可用于治疗和/或预防钠通道介导的疾病或病症如疼痛。

公开(公告)号：US20140256736A1

公开(公告)日：2014-09-11

申请号：US14355549

申请日：2012-10-30

Applicant: XENON PHARMACEUTICALS INC.

Inventor： Shifeng Liu ,  Thilo Focken ,  Navjot Chahal ,  Zaihui Zhang ,  Renata Marcella Oballa ,  Julia Fonarev

IPC: C07D487/04 ,  C07D417/12 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D403/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D473/00

Abstract: This invention is directed to biaryl ether sulfonamides, or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract translation: 本发明涉及用于治疗和/或预防钠通道介导的疾病或病症如疼痛的联芳基醚磺酰胺或其药学上可接受的盐，溶剂合物或前药。

公开(公告)号：US20130317001A1

公开(公告)日：2013-11-28

申请号：US13899526

申请日：2013-05-21

Applicant: XENON PHARMACEUTICALS INC. ,  GENENTECH, INC.

Inventor： Jean-Christophe Andrez ,  Sultan Chowdhury ,  Shannon Marie Decker ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Ivan William Hemeon ,  Qi Jia ,  Jun Li ,  Daniel F. Ortwine ,  Brian Safina ,  Tao Sheng ,  Shaoyi Sun ,  Daniel P. Sutherlin ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D403/12 ,  C07D213/64 ,  C07D205/04 ,  C07D311/58 ,  C07D295/26 ,  C07D233/84 ,  C07D257/04 ,  C07C311/51 ,  C07C307/06 ,  C07D213/82 ,  C07D265/30

CPC classification number: C07D491/107 ,  A61K31/18 ,  A61K31/397 ,  A61K31/40 ,  A61K31/41 ,  A61K31/4164 ,  A61K31/44 ,  A61K31/5375 ,  C07B2200/05 ,  C07C307/06 ,  C07C311/51 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/10 ,  C07C2602/18 ,  C07C2602/20 ,  C07C2602/42 ,  C07C2602/44 ,  C07C2602/50 ,  C07C2603/66 ,  C07C2603/68 ,  C07C2603/74 ,  C07D205/04 ,  C07D207/46 ,  C07D207/48 ,  C07D209/52 ,  C07D211/22 ,  C07D211/96 ,  C07D213/64 ,  C07D213/82 ,  C07D233/84 ,  C07D257/04 ,  C07D265/30 ,  C07D295/192 ,  C07D295/26 ,  C07D307/12 ,  C07D307/18 ,  C07D309/08 ,  C07D311/58 ,  C07D311/70 ,  C07D311/72 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12 ,  C07D451/02 ,  C07D471/08

Abstract: The invention provides novel compounds having the general formula: and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, B, R1, R2, R3, R4, R5 and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

公开(公告)号：US20250059189A1

公开(公告)日：2025-02-20

申请号：US18746981

申请日：2024-06-18

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Verner Alexander LOFSTRAND ,  Jung Yun KIM ,  Helen CLEMENT ,  Kristen Nicole BURFORD ,  Paul CHARIFSON ,  Shawn JOHNSTONE ,  Juliette SABBATANI ,  Jan Felix SCHOLTES ,  Wei ZHANG ,  Shaoyi SUN

IPC: C07D471/04 ,  C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D487/04 ,  C07D491/052

Abstract: The present disclosure is directed to compounds of formula (I): wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US20230405023A1

公开(公告)日：2023-12-21

申请号：US18248663

申请日：2021-04-09

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Gregory N. Beatch ,  Rostam Namdari

IPC: A61K31/635 ,  A61K31/4166

CPC classification number: A61K31/635 ,  A61K31/4166

Abstract: Provided are methods for treating diseases or conditions associated with Nav1.6 activity in a patient, comprising administering to said patient (S)-4((1-benzylpyrrolidin-3-yl)(methypamino)-2-fluoro-5-methyl-N(thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof, wherein the patient is also being administered a strong inducer of cytochrome P450 3A4 (CYP3A4).

公开(公告)号：US20230203007A1

公开(公告)日：2023-06-29

申请号：US17951644

申请日：2022-09-23

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Verner Alexander Lofstrand ,  Jung Yun Kim ,  Helen Clement ,  Kristen Nicole Burford ,  Paul Charifson ,  Shawn Johnstone ,  Juliette Sabbatani ,  Jan Felix Scholtes ,  Wei Zhang ,  Shaoyi Sun ,  Michael Clark ,  Steve Wesolowski ,  Ravi Munuganti ,  Ramkumar Rajamani

IPC: C07D401/14 ,  C07D401/04 ,  C07D487/04 ,  C07D403/04 ,  C07D403/14 ,  C07D413/14 ,  C07D213/82 ,  C07D213/74 ,  C07D491/107 ,  C07D498/08 ,  C07D471/10 ,  C07D471/08 ,  C07D487/10 ,  C07D417/14 ,  C07D405/14 ,  C07D471/04 ,  C07D471/14 ,  C07F7/08

CPC classification number: C07D401/14 ,  C07D213/74 ,  C07D213/82 ,  C07D401/04 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D471/14 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D498/08 ,  C07F7/0812

Abstract: The present disclosure is directed to compounds of formula (I):





wherein R1, R2, R3, R3a, R4, Y, and X are as described herein, as stereoisomers, enantiomers, or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates, or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US20230144095A1

公开(公告)日：2023-05-11

申请号：US17951640

申请日：2022-09-23

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Verner Alexander Lofstrand ,  Jung Yun Kim ,  Helen Clement ,  Kristen Nicole Burford ,  Paul Charifson ,  Shawn Johnstone ,  Juliette Sabbatani ,  Jan Felix Scholtes ,  Wei Zhang ,  Shaoyi Sun

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D491/052 ,  C07D487/04

CPC classification number: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D401/04 ,  C07D491/052 ,  C07D487/04

Abstract: The present disclosure is directed to compounds of formula (1):




wherein X, Y, R1, R2 and R3 are as described herein, as stereoisomers, enantiomers or tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, and pharmaceutical compositions comprising the compounds of formula (I), as described herein, which are useful as voltage-gated sodium channel modulators and are therefore are useful in treating seizure disorders such as epilepsy.

公开(公告)号：US20220348570A1

公开(公告)日：2022-11-03

申请号：US17183401

申请日：2021-02-24

Applicant: Xenon Pharmaceuticals Inc.

Inventor： Jean-Christophe Andrez ,  Kristen Nicole Burford ,  Christoph Martin Dehnhardt ,  Thilo Focken ,  Michael Edward Grimwood ,  Qi Jia ,  Verner Alexander Lofstrand ,  Shaoyi Sun ,  Steven Sigmund Wesolowski ,  Michael Scott Wilson ,  Alla Yurevna Zenova

IPC: C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/12 ,  C07D471/04 ,  C07D487/08

Abstract: This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.